stockportfolio.pro
MCK vs REGN: Which Stock Is the Better Buy?
McKesson Corporation and Regeneron Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — MCK vs REGN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| McKesson Corporation (MCK) | Regeneron Pharmaceuticals, Inc. (REGN) | |
|---|---|---|
| Market cap | $92.1B | $68.6B |
| Revenue (latest FY) | $403.43B | $14.34B |
| Net income (latest FY) | $4.76B | $4.50B |
| Revenue growth (5y CAGR) | 11.1% | 11.0% |
| Net margin | 1.2% | 31.4% |
| Return on equity | -219.2% | 14.4% |
| P/E ratio | 20.5 | 16.0 |
| Dividend yield | 0.4% | 0.6% |
| Profitable years (of last 10) | 9 | 10 |
| Positive free cash flow | Yes | Yes |
See the full MCK vs REGN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open MCK's full financials → Open REGN's full financials →Frequently asked questions
Which is bigger, MCK or REGN?
McKesson Corporation is larger by market capitalization — $92.1B versus $68.6B.
Which grows faster, MCK or REGN?
Over the last five fiscal years, McKesson Corporation grew revenue faster — 11.1%/yr versus 11.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
MCK fundamentals → · REGN fundamentals → · All 1,500+ companies → · Free screener →